Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ: HRMY )

32.72 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,131
Open 32.82
Bid (Size) 32.67 (11)
Ask (Size) 32.73 (11)
Prev. Close 32.72
Today's Range 32.06 - 33.05
52wk Range 28.14 - 41.61
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire

Performance

YTD
-6.06%
-6.06%
1 Month
-16.26%
-16.26%
3 Month
-1.03%
-1.03%
6 Month
-15.58%
-15.58%
1 Year
+2.31%
+2.31%

More News

Read More
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews
Via Benzinga
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For February 25, 2025
Via Benzinga
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews
Via Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
NASDAQ:HRMY is not too expensive for the growth it is showing.
Via Chartmill
Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Via Benzinga
Exposures Product Safety
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
Via Investor's Business Daily
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
Via Chartmill
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
NASDAQ:HRMY, a growth stock which is not overvalued.
Via Chartmill
Friday's after hours session: top gainers and losers
Via Chartmill
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Via Investor's Business Daily
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
From Harmony Biosciences
Via Business Wire
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Via Chartmill
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.